BIIB (STOCKS)
Biogen Inc. Common Stock
$197.885000
-2.165000 (-1.08%)
Prev close: $200.050000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Christopher A. Viehbacher
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $29,215.17M
- Employees
- 7,605
- P/E (TTM)
- 21.47
- P/B (TTM)
- 1.58
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
18
Buy
16
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$3.57 | $2.83 | +0.7442 | +26.34% |
|
Dec 2025 (Q4)
|
$1.99 | $1.65 | +0.3436 | +20.87% |
|
Sep 2025 (Q3)
|
$4.81 | $3.96 | +0.8505 | +21.48% |
|
Jun 2025 (Q2)
|
$5.47 | $3.94 | +1.5325 | +38.92% |
Financial Statements
| Revenues | $9.94B |
| Benefits Costs and Expenses | $8.31B |
| Cost Of Revenue | $2.44B |
| Costs And Expenses | $8.31B |
| Gross Profit | $7.50B |
| Operating Expenses | $5.88B |
| Selling, General, and Administrative Expenses | $2.47B |
| Other Operating Expenses | $3.41B |
| Operating Income/Loss | $1.62B |
| Income/Loss From Continuing Operations After Tax | $1.37B |
| Income/Loss From Continuing Operations Before Tax | $1.62B |
| Income Tax Expense/Benefit | $251.10M |
| Income Tax Expense/Benefit, Deferred | $413.00M |
| Interest Expense, Operating | $275.10M |
| Net Income/Loss | $1.37B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $1.37B |
| Net Income/Loss Available To Common Stockholders, Basic | $1.37B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $9.35 |
| Diluted Earnings Per Share | $9.30 |
| Basic Average Shares | 440,400,000 |
| Diluted Average Shares | 442,500,000 |
| Assets | $29.48B |
| Current Assets | $9.19B |
| Inventory | $1.95B |
| Other Current Assets | $7.24B |
| Noncurrent Assets | $20.29B |
| Fixed Assets | $3.02B |
| Intangible Assets | $9.05B |
| Other Non-current Assets | $8.22B |
| Liabilities | $10.83B |
| Current Liabilities | $3.00B |
| Accounts Payable | $358.50M |
| Other Current Liabilities | $2.64B |
| Noncurrent Liabilities | $7.83B |
| Long-term Debt | $6.29B |
| Other Non-current Liabilities | $1.54B |
| Equity | $18.65B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $18.65B |
| Liabilities And Equity | $29.48B |
| Net Cash Flow From Operating Activities | $2.59B |
| Net Cash Flow From Operating Activities, Continuing | $2.59B |
| Net Cash Flow From Investing Activities | -$1.53B |
| Net Cash Flow From Investing Activities, Continuing | -$1.53B |
| Net Cash Flow From Financing Activities | -$322.70M |
| Net Cash Flow From Financing Activities, Continuing | -$322.70M |
| Exchange Gains/Losses | $49.60M |
| Net Cash Flow | $784.40M |
| Net Cash Flow, Continuing | $734.80M |
| Comprehensive Income/Loss | $1.41B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $1.41B |
| Other Comprehensive Income/Loss | $34.30M |
| Other Comprehensive Income/Loss Attributable To Parent | -$44.30M |